Posts Tagged ‘Op-ed-CO-SB19’
“…barriers will delay or prevent drug importation,” say regulatory experts
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
[...]“These drugs would go through additional shipping, inspection and repackaging. Why would they be cheaper?”
In this editorial, which was published in WBUR’s Cognoscenti on September 2, 2020, writer Sarah Ruth Bates explains why Canadian drug importation is too expensive and elaborate a solution to be effective.
[...]Canadian patient advocate urges American friends to reject the “empty promises” of importation
In this August 14, 2020 editorial, Best Medicines Coalition chair John Adams explains why Canadian importation will not lower U.S. medicine prices—and why the “concept of cheap drugs from Canada has never been anything more than a political hallucination.”
[...]Former FDA Associate Commissioner Warns of the “Massive Safety Risks of Importation”
Source: Twitter This editorial by Peter J. Pitts was published in The Times Weekly on March 3, 2020. Mr. Pitts is president of the Center for Medicine in the Public Interest and a former FDA associate commissioner. Keep Canadian drugs out of U.S. medicine cabinets The Trump administration recently proposed two rules that would allow…
[...]Canadian drug importation is “an economic fantasy,” former Canadian health minister says.
In this editorial in The Globe and Mail, Ujjal Dosanjh, formerly a federal minister of health and a premier of British Columbia, explains that drug manufacturers have no incentive to sell Canadian provinces more medicine to fill the needs of U.S. residents. Importation will lead to drug shortages in Canada and counterfeit drug trafficking to the U.S.
[...]Canadian health law experts predict: Canada won’t end up as the drugstore to the U.S.
This editorial by David C. Rosenbaum and Dara Jospé was published in the Financial Post on January 16, 2020. Rosenbaum is a partner of the law firm Fasken. Jospé is an associate for the same company.
[...]Academic Warns That State Drug Importation Proposals Threaten Patients and Innovation
This editorial by Dr. Kristina M. L. Acri née Lybecker was published in IP Watchdog on January 2, 2020. Dr. Acri is an Associate Professor of Economics at Colorado College in Colorado Springs, and Chair of the Department of Economics and Business.
[...]Emory Health Policy Professor Says Drug Importation a Danger to Patient Health
This editorial by Dr. Kenneth E. Thorpe was published in Town Hall on October 8, 2019. Dr. Thorpe is a professor of health policy at Emory University and chairman of the Partnership to Fight Chronic Disease.
[...]Pharmacy professor: buying prescription drugs from Canada “risky in terms of quality and safety”
This editorial by C. Michael White was published in The Conversation on September 27, 2019. White is a professor and head of the Department of Pharmacy Practice for the University of Connecticut.
[...]Former FDA Associate Commissioner Says Canada Cannot Be America’s Pharmacy
This editorial by Peter J. Pitts was published in The Washington Times on September 11, 2019. Mr. Pitts is president of the Center for Medicine in the Public Interest and a former FDA associate commissioner.
[...]